Cargando…
Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
With an incidence of 68 new cases per 100,000 people per year, an estimated total number of up to 350,000 new non-small-cell lung cancer (NSCLC) cases are diagnosed each year in the European Union. Up to 10% of NSCLC patients are eligible for therapy with novel ALK (anaplastic lymphoma kinase) inhib...
Autores principales: | Nenadić, Ilija, Staber, Janine, Dreier, Susanne, Simons, Guus, Schildgen, Verena, Brockmann, Michael, Schildgen, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532624/ https://www.ncbi.nlm.nih.gov/pubmed/28696381 http://dx.doi.org/10.3390/cancers9070088 |
Ejemplares similares
-
Microsatellite instability testing in colorectal cancer using the QiaXcel advanced platform
por: Förster, Isabel, et al.
Publicado: (2018) -
Human bocavirus is detected in human placenta and aborted tissues
por: Hansen, Max, et al.
Publicado: (2018) -
Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT(2)-Profiler Multiplex RT-PCR
por: Schildgen, Verena, et al.
Publicado: (2019) -
Limits and Opportunities of SARS-CoV-2 Antigen Rapid Tests: An Experienced-Based Perspective
por: Schildgen, Verena, et al.
Publicado: (2021) -
Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis
por: Gupta, Aastha, et al.
Publicado: (2022)